Nutrisense BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Nutrisense a Legitimate Company?

Nutrisense operates as a registered business offering continuous glucose monitor (CGM) hardware paired with dietitian coaching through a mobile app. The company sources FDA-cleared CGM devices from Abbott and Dexcom, which are regulated under 510(k) clearances that the FDA maintains in its device database. Nutrisense itself does not manufacture a medical device, so its own FDA registration footprint is limited to its role as a distributor and software-adjacent service.

Corporate Registration and BBB Standing

Nutrisense Inc. Is incorporated in Delaware and holds a BBB accreditation. Its rating has moved between A and A+ depending on the volume and resolution speed of open complaints in any given quarter. The BBB scoring formula weighs complaint volume relative to business size, response time, and resolution outcome. A rating in the A range does not certify a product works as advertised; it reflects complaint-handling behavior only.

As of mid-2025, the BBB profile for Nutrisense shows several dozen closed complaints over a three-year window. That volume is low relative to comparable subscription-health companies but is not zero. Consumers browsing the profile will find that most complaints were marked "resolved" or "answered," meaning Nutrisense responded formally even when the consumer was not satisfied.

What BBB Ratings Do and Do Not Tell You

The BBB is a private, membership-funded organization. Its ratings are not a government certification and are not endorsed by the FDA, the FTC, or any state medical board. The FTC has published guidance noting that BBB ratings should be read alongside complaint narratives rather than used as a standalone trust signal. Consumers relying solely on a letter grade to assess a health service are using an incomplete signal.

What Are the Most Common Nutrisense Complaints?

Billing disputes account for the largest share of formal complaints. Subscription cancellation difficulty is the second most frequent category. Clinical dissatisfaction (feeling the coaching did not change glucose outcomes) appears in narrative reviews on third-party platforms but rarely escalates to formal regulatory filings.

Billing and Auto-Renewal Disputes

The most consistent theme across BBB complaint narratives, Trustpilot reviews, and Reddit threads is that users felt the auto-renewal terms were not clearly disclosed at sign-up. This is a structural problem in subscription-health broadly, not unique to Nutrisense. The FTC's Negative Option Rule, finalized in 2023 and codified at 16 C.F.R. Part 425, requires that subscription auto-renewal terms be disclosed clearly before a consumer completes a purchase and that cancellation must be as easy as sign-up. Complaints suggesting Nutrisense made cancellation difficult are therefore potentially within the FTC's enforcement scope, though no public FTC action against Nutrisense has been filed as of this writing.

The FDA's MedWatch database, searchable at FDA MedWatch, contains adverse event reports tied to the CGM hardware itself (Abbott FreeStyle Libre, Dexcom G7) but not to Nutrisense's coaching service. Skin irritation from CGM adhesives is the most frequently reported hardware adverse event across all CGM brands, with Abbott's FreeStyle Libre receiving the majority of adhesive-related MedWatch submissions industry-wide.

Coaching Quality and Dietitian Responsiveness

Several verified reviews cite delayed responses from assigned dietitians, particularly in the first two weeks of a subscription when users need the most guidance interpreting glucose data. Nutrisense's model pairs each subscriber with a registered dietitian (RD), not a physician or nurse practitioner. RDs are licensed at the state level under dietetics practice acts, not under medical board jurisdiction, which limits the regulatory avenues available to dissatisfied consumers.

The Academy of Nutrition and Dietetics outlines RD scope of practice standards that prohibit RDs from diagnosing conditions or prescribing medications. Nutrisense's service sits within that scope, meaning it does not constitute medical practice. That framing also means consumers cannot file a state medical board complaint if they feel the coaching was ineffective, because no medical license is in play.

Refund and Cancellation Outcomes

Of the BBB complaints with documented outcomes, most ended with a partial credit, a waived upcoming charge, or a full refund of the most recent billing cycle. Very few resulted in no resolution at all. That pattern suggests Nutrisense's customer-service team is responsive to formal escalation even when it resists informal cancellation requests. Consumers who reach an impasse should file a complaint directly with the BBB, which triggers a 14-day response window under BBB's operating standards.

Does Nutrisense Use FDA-Cleared Devices?

Yes. The CGM sensors Nutrisense ships are FDA-cleared Class II devices. The Abbott FreeStyle Libre 3 received 510(k) clearance (K220569) and is listed in the FDA's 510(k) premarket notification database at FDA 510(k) database. The Dexcom G7 received its own 510(k) clearance (K221725), also searchable at the same FDA database. Nutrisense acts as a retail distributor of these cleared sensors, not as a device manufacturer.

CGM Accuracy and Clinical Validity

CGM accuracy is measured by mean absolute relative difference (MARD). The Abbott FreeStyle Libre 3 has a MARD of approximately 7.9% in key studies submitted to the FDA. A prospective study published in Diabetes Technology and Therapeutics (Haak et al., 2017, N=102) reported that the FreeStyle Libre system met ISO 15197:2013 accuracy standards in 99.7% of paired readings. The Dexcom G7 achieved a MARD of 8.2% in its key trial (N=112 adults), as reported in the FDA summary of safety and effectiveness data.

These accuracy figures apply to people with diabetes using the devices for glucose management. Whether real-time CGM data provides actionable benefit to metabolically healthy adults (Nutrisense's primary target market) is a separate evidence question.

CGM in Metabolically Healthy Adults: What the Evidence Says

A randomized controlled trial published in JAMA Internal Medicine (Ehrhardt et al., 2023, N=153) found that CGM-guided interventions in adults without diabetes did not produce statistically significant improvements in HbA1c, fasting glucose, or body weight at 12 months compared to standard dietary advice. The authors noted that "CGM use in people without diabetes may not translate to the metabolic improvements seen in diabetic populations," a finding directly relevant to Nutrisense's marketing claims about glucose optimization in healthy users.

A separate pilot study in Nutrients (Hall et al., 2018, N=57) found that continuous glucose data combined with dietary coaching reduced postprandial glucose spikes by 14% over eight weeks, though the study lacked a control arm and was funded in part by a CGM manufacturer. These two data points sit in tension: short-term coaching may shift postprandial responses, but longer-term metabolic outcomes in non-diabetic users remain unproven at the level of randomized evidence.

The American Diabetes Association's Standards of Medical Care in Diabetes (2024 edition) does not currently recommend CGM for adults without a diabetes diagnosis, stating that "evidence supporting CGM use in individuals without diabetes is insufficient to support routine clinical recommendation." That guideline position at ADA Standards of Care is the most authoritative current summary of where clinical consensus stands.

How to Evaluate Any CGM Coaching Service Before Subscribing

Consumers assessing Nutrisense or any comparable CGM subscription should apply a five-question framework before entering a billing relationship.

Question 1: Is the CGM Hardware FDA-Cleared?

Confirm the specific sensor model against the FDA's 510(k) database at FDA 510(k) database. A cleared sensor does not mean the coaching service is regulated, but uncleared hardware would be a red flag requiring immediate escalation to the FDA's MedWatch system.

Question 2: Who Provides Clinical Oversight?

Nutrisense uses registered dietitians, not physicians. If your primary goal involves managing a diagnosed metabolic condition (pre-diabetes, type 2 diabetes, insulin resistance confirmed by lab work), a service with physician oversight and the ability to prescribe medications may be more appropriate. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy, available at Endocrine Society guidelines, outlines when lifestyle intervention alone is insufficient and pharmacotherapy should be added.

Question 3: What Are the Auto-Renewal Terms?

Read the terms of service before providing a payment method. Under the FTC Negative Option Rule at FTC Negative Option Rule, any subscription that charges automatically must disclose renewal terms clearly, provide a simple cancellation mechanism, and send a reminder before billing. If a company's cancellation process requires a phone call during limited hours, that may itself violate the rule.

Question 4: Is There a Money-Back or Trial Period?

Nutrisense has offered a partial refund window (typically 30 days) on hardware but not on the coaching subscription fee in most billing periods. Verify current refund policy in writing via the company's support channel before subscribing, and save the response as documentation.

Question 5: What Outcome Does the Service Actually Measure?

CGM data shows interstitial glucose patterns. It does not directly measure insulin sensitivity, HbA1c, cardiovascular risk, or visceral fat. If you want to track those outcomes, request a metabolic panel from a primary care provider. The CDC's National Diabetes Prevention Program, described at CDC NDPP, offers evidence-based lifestyle coaching (24 sessions over 12 months, 5% to 7% weight-loss target) that has been validated in randomized trials including the Diabetes Prevention Program Outcomes Study (N=3,234, 34% relative risk reduction in diabetes incidence at 10 years).

Regulatory Field for CGM-as-a-Service

No federal agency currently certifies CGM coaching programs as medical interventions. The FDA regulates the device hardware; state dietetics boards regulate the RDs providing coaching; the FTC regulates advertising claims and subscription terms. That three-agency split creates coverage gaps that allow companies to make broad wellness claims without meeting the evidentiary bar required for medical device or drug labeling.

FDA Oversight of CGM Labeling

The FDA's Office of In Vitro Diagnostics oversees CGM device labeling. Manufacturers cannot claim their devices diagnose, treat, or prevent disease beyond their cleared indications. A distributor like Nutrisense inherits the cleared indications of the underlying hardware but cannot expand those claims through marketing materials without its own regulatory pathway. The FDA's guidance on laboratory developed tests and wellness devices, searchable at FDA guidance documents, is the relevant reference for understanding where distributor-level marketing claims are policed.

FTC Advertising Enforcement

The FTC Act, Section 5, prohibits unfair or deceptive acts in commerce. The FTC has taken enforcement action against health tech companies for unsubstantiated efficacy claims. Its Health Products Compliance Guidance (2022) specifies that "competent and reliable scientific evidence" for health benefit claims requires "tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified persons and that are generally accepted in the relevant scientific fields." Nutrisense's website language around "metabolic health optimization" and "understanding your glucose" is soft enough that it has not drawn a public FTC action, but consumers should treat such language as aspirational rather than clinically proven.

State Dietetics Board Oversight

RDs practicing across state lines through telehealth must comply with licensure requirements in the patient's home state. As of 2025, 26 states participate in the Nutrition and Dietetics Interstate Compact (NDIEC), which allows RDs to provide telehealth services across compact states under a single multistate license. Consumers in non-compact states who receive dietitian coaching from an RD not licensed in their state could potentially file a complaint with their state's dietetics licensing board, though enforcement actions are rare.

LegitScript and Third-Party Certification

LegitScript is a verification and monitoring company that certifies online pharmacies and telehealth providers. Its certification is required by Google, Meta, and other ad platforms for health companies running paid advertising. Nutrisense does not operate as an online pharmacy (it does not dispense prescription medications), so it does not fall under LegitScript's pharmacy certification program. LegitScript's telehealth certification program, described at LegitScript, covers providers that prescribe or dispense controlled substances or prescription drugs. Because Nutrisense's service does not include prescription dispensing, its absence from the LegitScript certified list is neither a red flag nor a green flag specific to this company.

How Nutrisense Compares to Similar Services on Complaint Metrics

Direct numerical comparison across CGM subscription brands is limited by the fact that BBB complaint databases do not publish normalized complaint rates (complaints per 1,000 customers). Nutrisense, Levels Health, and January AI are the three largest CGM coaching subscription services in the U.S. Market as of 2025. Levels Health operates an invitation-based model and does not hold BBB accreditation, making direct comparison impossible through that channel. January AI positions itself as AI-driven rather than dietitian-driven and has a smaller complaint footprint, partly because its subscriber base is smaller.

What can be said is that the complaint categories across all three services are structurally similar: billing transparency, cancellation difficulty, and outcome expectations that outpace results. That pattern reflects the subscription-health model broadly. A 2022 analysis published in JAMA (Mehrotra et al., 2022) examining direct-to-consumer telehealth services found that "billing disputes and unmet expectations about clinical outcomes were the dominant themes in consumer complaints across 14 DTC health platforms reviewed." The study covered behavioral health and primary care platforms but the structural finding applies to CGM coaching services with comparable subscription architectures.

What to Do If You Have a Complaint Against Nutrisense

If informal resolution through Nutrisense customer service fails, consumers have four escalation channels.

File a BBB Complaint

Submit a complaint at bbb.org. Nutrisense is obligated to respond within 14 days under BBB operating procedures. BBB complaints become part of the company's public profile and factor into its rating.

File an FTC Report

The FTC's consumer complaint portal at FTC ReportFraud accepts reports about deceptive subscription practices. Individual reports do not trigger individual investigations but feed into the FTC's pattern-detection system for enforcement prioritization.

File an FDA MedWatch Report

If you experienced a physical adverse event related to the CGM hardware (skin reaction, inaccurate readings that led to a clinical decision, sensor failure), file a MedWatch report at FDA MedWatch. Hardware adverse events should be attributed to the device manufacturer (Abbott or Dexcom) and will be routed accordingly.

Contact Your State Attorney General

State attorneys general have consumer protection jurisdiction over subscription billing practices. If you believe Nutrisense violated your state's auto-renewal law (43 states have them as of 2025), a complaint to the AG's consumer protection division may carry more enforcement weight than a BBB filing.

Consumers who believe they received health advice that constituted unlicensed medical practice should contact their state's dietetics licensing board and, if a physician was involved at any point in the interaction, their state medical board.